Congress Should Support Access to Post-Conviction DNA Testing
By Kirk Bloodsworth,
The Hill
| 07. 29. 2015
I'll never forget how lonely I felt when the jury announced its guilty verdict and the courtroom erupted in applause. I thought, how could this happen? It felt surreal, but soon after reality sunk in: I could spend the rest of my life in prison until the state of Maryland executed me. I spent eight years, 11 months and 19 days locked away — two of those years on death row — for a rape and murder that I did not commit, before post-conviction DNA testing proved my innocence.
If not for post-conviction DNA testing, I might still be in prison, or worse, I could have been executed. In 1993, I became the first death-row inmate in the U.S. to be exonerated by DNA testing. Since then, I have dedicated my life to advocating for reforms that will both prevent and identify wrongful convictions.
Recently I had the opportunity to make a case for criminal justice reform as a participant in the Coalition for Public Safety’s and Cut50’s Bipartisan Fair Justice Summit. This year, Congress can support reform by passing...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...